Kivu Bioscience

Kivu Bioscience is a pioneer in the field of oncology for next-generation antibody-drug conjugates (ADCs). The company's proprietary linker-payload technology offers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC projects in development and a team of industry veterans, Kivu is advancing its first two lead candidates into clinical trials, which are expected to commence in 2025.